The economic costs of knee osteoarthritis (OA) and its treatment are important considerations for patients, physicians, and healthcare systems when making decisions about the management of knee OA, especially given the direct costs associated with total knee replacement (TKR) [1, 2] , and the estimated increase in demand by 2030 projected for TKR in the United States (673% increase from 2005 for primary TKR) [3] .
Viscosupplementation has been shown to delay the time to TKR [4] [5] [6] [11]) using a single payer perspective similar to the approach taken by Rosen et al. [7] .
Synvisc-One may also be more appropriate than Durolane to include in this analysis because, unlike Durolane, Synvisc-One is FDA-approved. Our model focuses on OA patients C60 years of age and assumes a conservative estimate (based on previous reports [4, 12] ) that 20% of these patients will receive IA-HA treatment. Given that 18.5% of the US population is C60 years of age [13] and that the prevalence of knee OA is 37.4% among adults [14] Our model includes the direct costs of the product itself and the cost of administration.
However, patients may experience additional burden associated with direct as well as indirect costs attributable to an increased number of office visits for those additional injections. Patients would likely have to pay additional co-payments for those visits. Moreover, patients may experience higher indirect costs such as loss of salary due to utilization of work time for injection visits, the need to use employer-provided time off, and cost of travel to the physician. Our concerns with the Rosen et al. article [7] do not pertain solely to the exclusion of Synvisc-One from the analysis. It could be argued that it is not surprising the cost of a medication administered only twice a year is lower than that of a medication administered six times a year. However, when Euflexxa is compared with a 3-injection regimen of either Hyalgan or Supartz (as was used in Rosen et al. Second, we have concerns regarding the methodology used to extract data from the selected studies. Because cost-effectiveness evaluation is a comparison of incremental efficacy gained given cost, the efficacy data selected must be comparable. In the Rosen et al. analysis [7] , however, the data from one of the five articles that met the selection criteria set forth by the authors, the Altman et al. article [15] , was not used directly in their analysis.
Rather, utility scores for Euflexxa were secondarily abstracted from a different article, Hatoum et al. [16] , which is a cost-effectiveness analysis of the data in the Altman et al. article [15] . The data in Altman et al. [15] that were analyzed in Hatoum et al. [16] were also reported on a 100-mm visual analog scale rather than on the 5-point Likert scale format set forth as a requirement for the study selection, and were from both a randomized controlled study (as per the selection approach) and an open-label extension study that followed it. Given the different approaches used to convert efficacy data into utility data, it is difficult to interpret the baseline utility scores for the different products presented in Rosen et al. [7] , which differ substantially. In addition to differences in data conversion contributing to differences in utility scores, variability may also result from efficacy differences among products in similar patient populations and/or similar efficacy but in varying patient populations. It is very difficult to reliably interpret the scores given in the article without information on factors that may contribute to variability in the analysis.
In conclusion, measuring cost-effectiveness depends on both cost and efficacy measures, which in the end depend on the integrity of the data used, how representative they are, and the model applied. A more direct, and therefore, more accurate approach, which has been used for other diseases ranging from pain and generalized anxiety disorders [17] to fibromyalgia [18] , would be to assess health-related quality-of-life and utility measures directly as outcome measures in clinical trials. This would clarify the data collection and extraction processes, making comparisons easier to interpret within a real-world context for all users of the treatment. In considering cost-effectiveness of IA-HA treatments for OA, specifically, the issue becomes complicated by the delivery method needed for viscosupplementation. An increase in the number of injections is associated not only with the cost of the treatment and the cost of administration but also with additional direct costs (e.g., additional co-payments) and with indirect costs such as requiring time off from work. Therefore, these considerations must be included in a comprehensive evaluation of the cost-effectiveness of these products. Although Rosen et al. [7] acknowledge that this cost analysis represents ''a single payer, base-case scenario,'' they do 
